Surrozen

company

About

Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.

  • 51 - 100

Details

Last Funding Type
Series B
Last Funding Money Raised
$50M
Industries
Biotechnology,Emergency Medicine,Health Care
Founded date
Jan 1, 2016
Number Of Employee
51 - 100
Operating Status
Active

Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas and central nervous system.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$50M
Surrozen has raised a total of $50M in funding over 2 rounds. Their latest funding was raised on Mar 15, 2019 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 15, 2019 Series B $50M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Surrozen is funded by 1 investors. Hartford HealthCare Endowment are the most recent investors.
Investor Name Lead Investor Funding Round
Hartford HealthCare Endowment Series B